	Application No.	Applicant(s)
Notice of Allowability	10/699,898	BOWEN ET AL.
	Examiner	Art Unit
	Ling-Siu Choi	1713
The MAILING DATE of this communication appears on the cover sheet with the correspondence address— All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to the Amendment filed October 20, 2005.		
2. The allowed claim(s) is/are <u>2-5 and 7-22</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
		:
		:
		:
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5  Notice of Informal	Patent Application (PTO-152)
2. Notice of Notice of Praftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summary	
	Paper No./Mail Da	ate
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date</li> </ol>	8), 7. Examiner's Amend	ment/Comment
4. Examiner's Comment Regarding Requirement for Deposit of Biological Material		nent of Reasons for Allowance
	9.	· .
		:
		:

## **DETAILED ACTION**

This Office Action is in response to the Amendment filed October 20, 2005.
 Claims 1 and 6 were canceled and claims 21-22 have been added. Claims 2-5 and 7-22 are now pending.

## Examiner's Amendment

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CAR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Alvin T. Rockhill on January 6, 2006.

3. The application has been amended as follows:

Claim 20, line 1, change "claim 6" to --claim 22--.

## Allowable Subject Matter

4. Claims 2-5 and 7-22 are allowed.

Application/Control Number: 10/699,898

Art Unit: 1713

5. The following is an examiner's statement of reasons for allowance:

The present claims are allowable over the closest references: Ender (US 3,287,291), Nakamura et al. (US 5,973,067), and Britton (US 5,618,951).

Ender discloses an organosilicon compound represented by the formula of Si[(OCH<sub>2</sub>)<sub>n</sub>OCH<sub>3</sub>]<sub>4</sub> which includes Si(OCH<sub>2</sub>OCH<sub>3</sub>)<sub>4</sub>, Si[(OCH<sub>2</sub>)<sub>5</sub>OC<sub>4</sub>H<sub>9</sub>]<sub>4</sub>, Si(OCH<sub>2</sub>OC<sub>2</sub>H<sub>5</sub>)(OCH<sub>2</sub>OCH<sub>3</sub>) (OCH<sub>2</sub>OCH<sub>2</sub>OC<sub>2</sub>H<sub>5</sub>) (OCH<sub>2</sub>OCH<sub>3</sub>), Si(OCH<sub>2</sub>OCH<sub>3</sub>)[(OCH<sub>2</sub>)<sub>3</sub>OCH<sub>3</sub>] [(OCH<sub>2</sub>)<sub>2</sub>OCH<sub>3</sub>] [(OCH<sub>2</sub>)<sub>4</sub>OCH<sub>3</sub>] (col. 1, lines 15-20; col. 2, lines 14-26). However, Ender does not teach or fairly suggest the claimed modified compound containing acetal group and Ge, Sn, Pb, Ti, or Zr.

Nakamura et al. disclose an alkenyltrialkoxysilane which can be allyltrimethoxysilane, allyltriethoxysilane, allyltri(ethoxymethoxy)silane, butenyltrimethoxysilane, hexenyltrimethoxysilane, or hexaenyltriethoxysilane (claims 1 and 3). However, Nakamura et al. do not teach or fairly suggest the claimed modified compound containing acetal group and Ge, Sn, Pb, Ti, or Zr.

Britton discloses 2,2-difluoroketene silyl acetal (claim 1, Formula I). However, Britton. does not teach or fairly suggest the claimed modified compound containing acetal group and Ge, Sn, Pb, Ti, or Zr.

## Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ling-Siu Choi whose telephone number is 571-272-

**Art Unit: 1713** 

1098.

If attempt to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Wu, can be reach on 571-272-1114.

Page 4

LING-SUI CHOI PRIMARY EXAMINER

Lis-edi

January 6, 2006